アスピリンの心臓保護効果に対するイブプロフェンの効果
1Medicines Monitoring Unit, Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, DD1 9SY, Dundee, UK. t.m.macdonald@dundee.ac.uk
Lancet (London, England)
|February 25, 2003
まとめ
イブプロフェンと低用量アスピリンの併用は,既存の心血管疾患を有する患者の心血管疾患による死亡リスクを増やす可能性があります. この組み合わせ治療は,アスピリンの効果を否定する可能性がある.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- クリニカル・メディシン 臨床医学
背景:
- 低用量のアスピリンは,心血管疾患の患者の心臓保護のために広く使用されています.
- イブプロフェンなどの非ステロイド性抗炎症薬は,一般的に疼痛緩和に使用されます.
- アスピリンとイブプロフェンの間の潜在的な相互作用は,心血管疾患の結果に影響を与える可能性があります.
研究 の 目的:
- 低用量アスピリンとイブプロフェンの両方を服用している既定の心血管疾患を有する患者の心血管疾患による死亡リスクを調査する.
- イブプロフェンとアスピリンの併用が,アスピリンの心臓保護効果に影響するかどうかを評価する.
主な方法:
- 心血管疾患の最初の入院後に退院した7107人の患者のコホート研究.
- 患者は低用量アスピリン (<325 mg/日) を処方され,退院後少なくとも1ヶ月生存しました.
- アスピリンのみとアスピリンとイブプロフェンを併用した患者の死亡リスクの比較.
主要な成果:
- アスピリンとイブプロフェンを併用した患者は,あらゆる原因による死亡リスクの増加を示した (調整された危険比率は1.93).
- アスピリンとイブプロフェンを併用したグループでは,心血管疾患による死亡のリスクが著しく高かったことが観察されました (調整された危険比率1.73).
- この発見は,イブプロフェンとアスピリンの心臓保護効果の間の潜在的な相互作用を示唆しています.
結論:
- イブプロフェンと低用量のアスピリンの併用は,既定の心血管疾患を有する患者の死亡率の増加と関連しています.
- イブプロフェンは,アスピリンの心臓保護機構に干渉する可能性があります.
- 臨床医は,低用量アスピリン療法を受けている患者に,心血管保護のためにイブプロフェンを処方する際には注意を払うべきです.
関連する概念動画
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Factors Affecting Protein-Drug Binding: Drug Interactions
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...


